Zhong Zheng, Deng Xiaoqian, Wang Pengrui, Yu Claire, Kiratitanaporn Wisarut, Wu Xiaokang, Schimelman Jacob, Tang Min, Balayan Alis, Yao Emmie, Tian Jing, Chen Luwen, Zhang Kang, Chen Shaochen
Department of NanoEngineering, University of California San Diego, La Jolla, CA, 92093, USA.
Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Biomaterials. 2021 Jan;267:120462. doi: 10.1016/j.biomaterials.2020.120462. Epub 2020 Oct 23.
Ocular surface diseases including conjunctival disorders are multifactorial progressive conditions that can severely affect vision and quality of life. In recent years, stem cell therapies based on conjunctival stem cells (CjSCs) have become a potential solution for treating ocular surface diseases. However, neither an efficient culture of CjSCs nor the development of a minimally invasive ocular surface CjSC transplantation therapy has been reported. Here, we developed a robust in vitro expansion method for primary rabbit-derived CjSCs and applied digital light processing (DLP)-based bioprinting to produce CjSC-loaded hydrogel micro-constructs for injectable delivery. Expansion medium containing small molecule cocktail generated fast dividing and highly homogenous CjSCs for more than 10 passages in feeder-free culture. Bioprinted hydrogel micro-constructs with tunable mechanical properties enabled the 3D culture of CjSCs while supporting viability, stem cell phenotype, and differentiation potency into conjunctival goblet cells. These hydrogel micro-constructs were well-suited for scalable dynamic suspension culture of CjSCs and were successfully delivered to the bulbar conjunctival epithelium via minimally invasive subconjunctival injection. This work integrates novel cell culture strategies with bioprinting to develop a clinically relevant injectable-delivery approach for CjSCs towards the stem cell therapies for the treatment of ocular surface diseases.
包括结膜疾病在内的眼表疾病是多因素进展性疾病,会严重影响视力和生活质量。近年来,基于结膜干细胞(CjSCs)的干细胞疗法已成为治疗眼表疾病的一种潜在解决方案。然而,尚未有关于CjSCs高效培养或微创眼表CjSC移植疗法发展的报道。在此,我们开发了一种用于原代兔源CjSCs的强大体外扩增方法,并应用基于数字光处理(DLP)的生物打印技术来制备用于注射递送的负载CjSCs的水凝胶微构建体。含有小分子混合物的扩增培养基在无饲养层培养中使CjSCs快速分裂并高度均匀地传代超过10次。具有可调机械性能的生物打印水凝胶微构建体能够实现CjSCs的三维培养,同时维持其活力、干细胞表型以及向结膜杯状细胞分化的潜能。这些水凝胶微构建体非常适合CjSCs的可扩展动态悬浮培养,并通过微创结膜下注射成功递送至球结膜上皮。这项工作将新型细胞培养策略与生物打印技术相结合,为CjSCs开发了一种与临床相关的注射递送方法,用于眼表疾病治疗的干细胞疗法。